OBJECTIVE: This study assesses the cost-effectiveness of eltrombopag in the treatment of hepatitis C virus (HCV)-related thrombocytopenia. METHODS: A Markov model was constructed on the basis of the clinical trials ENABLE 1 and ENABLE 2. Three alternatives were considered: scenario 1; treatment with eltrombopag in both the enabling phase and during antiviral therapy, as in the ENABLE trial design; scenario 2; no eltrombopag treatment and no antiviral therapy; scenario 3; no eltrombopag treatment and subsequent administration of a reduced dose of peg-IFN. RESULTS: Base case results demonstrate that scenario 1 is associated with a cost per QALY of €30,020.94 in comparison with scenario 2. The incremental cost-effectiveness ratio reaches a value of €32,752.44 per QALY when scenario 1 is compared with scenario 3. CONCLUSION: The use of eltrombopag in HCV patients with thrombocytopenia is cost-effective as it leads to a reduction in disease progression and thus a drop in the number of patients with advanced liver disease.

Romano, F., Ruggeri, M., Coretti, S., Giannini, E., Sacchini, D., Annicchiarico, B., Marchetti, M., Rodeghiero, F., Lidonnici, D., Economic assessment of Eltrombopag in the treatment of thrombocytopenia, <<EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH>>, 2015; 15 (4): 713-720. [doi:10.1586/14737167.2015.1028373] [http://hdl.handle.net/10807/71774]

Economic assessment of Eltrombopag in the treatment of thrombocytopenia

Ruggeri, Matteo;Sacchini, Dario;
2015

Abstract

OBJECTIVE: This study assesses the cost-effectiveness of eltrombopag in the treatment of hepatitis C virus (HCV)-related thrombocytopenia. METHODS: A Markov model was constructed on the basis of the clinical trials ENABLE 1 and ENABLE 2. Three alternatives were considered: scenario 1; treatment with eltrombopag in both the enabling phase and during antiviral therapy, as in the ENABLE trial design; scenario 2; no eltrombopag treatment and no antiviral therapy; scenario 3; no eltrombopag treatment and subsequent administration of a reduced dose of peg-IFN. RESULTS: Base case results demonstrate that scenario 1 is associated with a cost per QALY of €30,020.94 in comparison with scenario 2. The incremental cost-effectiveness ratio reaches a value of €32,752.44 per QALY when scenario 1 is compared with scenario 3. CONCLUSION: The use of eltrombopag in HCV patients with thrombocytopenia is cost-effective as it leads to a reduction in disease progression and thus a drop in the number of patients with advanced liver disease.
Inglese
Romano, F., Ruggeri, M., Coretti, S., Giannini, E., Sacchini, D., Annicchiarico, B., Marchetti, M., Rodeghiero, F., Lidonnici, D., Economic assessment of Eltrombopag in the treatment of thrombocytopenia, <<EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH>>, 2015; 15 (4): 713-720. [doi:10.1586/14737167.2015.1028373] [http://hdl.handle.net/10807/71774]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10807/71774
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
social impact